ClinicalTrials.gg
CompletedNCT04410081Updated Mar 29, 2021

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

A Phase 1 interventional study of 14C-lazertinib in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to characterize the absorption, metabolic pathways of lazertinib, and the excretion of the parent lazertinib and its metabolites, after a single oral dose of 14C-lazertinib in healthy adult male participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be healthy on the basis of medical history performed at screening and physical examination and vital signs (pulse rate and body temperature) performed at screening and admission to the study site
  • Participants must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry or hematology panel are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not . This determination must be recorded in the participant's source documents and initialed by the investigator
  • (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m\^2, inclusive (BMI = weight/height\^2), and body weight not less than 50 kg at screening
  • Blood pressure at screening and admission to the study site (after the participant supine for 5 minutes) between 90 and 140 millimeter of Mercury (mmHg) systolic, inclusive; and no higher than 90 mmHg diastolic at screening
  • A 12-lead (ECG) consistent with normal cardiac conduction and function, including: Sinus rhythm, Pulse rate between 45 and 100 beats per minute (bpm), (QTc) interval less than or equal to (\<=) 450 millisecond (msec), QRS interval of less than (\<)120 msec, PR interval \<210 msec

Exclusion criteria

Exclusion Criteria:

  • History of infection suspected or confirmed to be related to Coronavirus disease 2019 (COVID-19) within 4 weeks before intake of study drug
  • Participant has known allergies, , or intolerance to lazertinib or any of its
  • Participant has a positive test for hepatitis A antibody immunoglobulin M (IgM), surface antigen (HBsAg), hepatitis B (anti-HBc or anti-HBs), or (anti-HCV) antibodies positive at screening. Hepatitis B surface antibody positivity is not exclusionary if participant can provide evidence of Hepatitis B vaccination
  • Participant who plans to father a child while enrolled in the study or within 6 months after study drug administration
  • Exposure to radiation for professional or medical reasons with the exception of up to 2 standard diagnostic radiographs (example, [dental X-rays, plain chest X-ray]) within 1 year before study drug administration on Study Day 1. Participants cannot have participated in a radiolabeled drug study within 12 months prior to dosing if the dose was higher than 0.1 megabecquerel (MBq)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    14C-lazertinib

    Participants will receive a single oral dose of 14C-lazertinib on Day 1.

    Drug: 14C-lazertinib

Interventions

  • A single oral dose of 14C-lazertinib will be administered.

    Also known as: JNJ-73841937

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of 14C-lazertinib

    Cmax is defined as maximum observed plasma concentration.

    Time frame: Up to 99 days

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of 14C-lazertinib

    Tmax is defined time to reach the maximum observed concentration.

    Time frame: Up to 99 days

  3. Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC [0-last]) of 14C-lazertinib

    AUC (0-last) is defined as area under the plasma concentration-time curve from time 0 to the time of last observed quantifiable concentration.

    Time frame: Up to 99 days

  4. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of 14C-lazertinib

    AUC (0-infinity) is defined as area under the plasma concentration-time curve from time 0 to infinity, calculated as the sum of AUC(0-last)+C(last)/ lambda(z), where C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

    Time frame: Up to 99 days

  5. Elimination Half-life (t1/2) of 14C-lazertinib

    Elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve, calculated as 0.693/lambda(z).

    Time frame: Up to 99 days

  6. Apparent Terminal Elimination Rate Constant (Lambda[z])

    Lambda(z) is defined as apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log transformed concentration vs time data.

    Time frame: Up to 99 days

  7. Total Apparent Clearance (CL/F) of 14C-lazertinib

    Clearance is a quantitative measure of the rate at which a drug substance is removed from the body, calculated as dose/AUC (0-infinity).

    Time frame: Up to 99 days

  8. Apparent Volume of Distribution (Vdz/F) of 14C-lazertinib

    Apparent volume of distribution, calculated as dose/(Lambda(z)\*AUC (0-infinity).

    Time frame: Up to 99 days

  9. Ratio of Blood to Plasma Total Radioactivity of 14C-lazertinib

    Blood to plasma total radioactivity ratio, calculated as blood total radioactivity/plasma total radioactivity.

    Time frame: Up to 99 days

  10. Ratio of AUC (0-infinity) of 14C-lazertinib to AUC (0-infinity) of Total Radioactivity in Plasma

    The ratio of AUC (0-infinity) of 14C-lazertinib to AUC (0-infinity) of total radioactivity in plasma will be assessed.

    Time frame: Up to 99 days

  11. Ratio of AUC (0-last) of 14C-lazertinib Concentration to AUC (0-last) of Total Radioactivity in Plasma

    The ratio of AUC (0-last) of 14C-lazertinib to AUC (0-last) of total radioactivity in plasma will be assessed.

    Time frame: Up to 99 days

  12. Ratio of Cmax of 14C-lazertinib to Cmax of Total Radioactivity in Plasma

    The ratio of Cmax of 14C-lazertinib to Cmax of total radioactivity in plasma will be assessed.

    Time frame: Up to 99 days

  13. Ratio of 14C-lazertinib Concentration to Total Radioactivity in Plasma

    The ratio of 14C-lazertinib concentration to total radioactivity in plasma for each sampling time point will be assessed.

    Time frame: Up to 99 days

  14. Amount of 14C-lazertinib Excreted in Urine (Ae[t1-t2])

    Amount excreted into the urine during a collection interval, where t1 and t2 are the start and end times of the collection interval, and calculated by multiplying the urinary volume with the urinary concentration for that interval.

    Time frame: Up to 99 days

  15. Cumulative Amount of 14C-lazertinib Excreted in Urine (Ae)

    Cumulative amount excreted into the urine over the entire collection period, calculated as the sum of Ae's across the collection intervals for each participant.

    Time frame: Up to 99 days

  16. Percentage of 14C-lazertinib Dose Excreted in Urine (%Ae)

    Cumulative amount excreted into the urine, expressed as a percentage of the administered dose, calculated as (Ae divided by dose)\*100.

    Time frame: Up to 99 days

  17. Renal Clearance (CLr) of 14C-lazertinib

    The CLr is the renal clearance of the drug, calculated as Ae/AUC(0-infinity).

    Time frame: Up to 99 days

  18. Amount of 14C-lazertinib Excreted in Feces (Fe[t1-t2])

    Amount excreted into the feces during a collection interval, where t1 and t2 are the start and end times of the collection interval, and calculated by multiplying the feces weight with the feces concentration for that interval.

    Time frame: Up to 99 days

  19. Cumulative Amount of 14C-lazertinib Excreted in Feces (Fe)

    Cumulative amount excreted into the feces over the entire collection period, calculated as the sum of Fe's across the collection intervals for each participant.

    Time frame: Up to 99 days

  20. Percentage of 14C-lazertinib Dose Excreted in Feces (%Fe)

    Cumulative amount excreted into the feces, expressed as a percentage of the administered dose, calculated as (Fe divided by dose)\*100.

    Time frame: Up to 99 days

  21. Total Recovery of 14C-lazertinib Dose in Feces and Urine

    Total recovery, calculated as sum of %Ae and %Fe.

    Time frame: Up to 99 days

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.

    Time frame: Up to 135 days

07

Study locations

1 site
  • PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Mar 2021, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
Jun 1, 2020
StartActual
Jul 14, 2020
Primary completionActual
Mar 2, 2021
CompletionActual
Mar 2, 2021
Last update
Mar 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04410081
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
Jul 14, 2020
Primary completion
Mar 2, 2021
Completion
Mar 2, 2021
Last update
Mar 29, 2021

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lazertinib

Start the discussion